Tal Teitz, PhD
Tal Teitz, PhD

Tal Teitz, PhD

Assistant Professor
School of Medicine, Omaha Campus

Academic Appointments

Department

  • Pharmacology and Neuroscience

Position

  • Assistant Professor

Biography

Publications and Presentations

Articles

  • BRAF Inhibition Protects Against Hearing Loss in Mice. Science Advances, 2020, Dec 2;6(49):eabd0561. doi: 10.1126/sciadv.abd0561. PMID:33268358., Science Advances, 6(49), eabd0561, 2020
  • Abstract
    There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogues of AT7519 and identified analogue 7, which exhibited an improved therapeutic index. When delivered locally, analogue 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity., Journal of Medicinal Chemistry, volume 61(17), 7700-7709, 2018

Publications

  • Ingersoll MA, Lutze R, Kresock DF, Malloy A, Caster LE, Holland E, Teitz T. Repurposing FDA-approved MEK inhibitor Trametinib for protection from cisplatin-induced hearing loss. June 3rd and 4th, 2021 Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA., 2021
  • Pushpan CK, Kresock DF, Ingersoll MA, Keirns DL, Hunter WJ, Bashir K, Teitz T. CDK2 inhibitor AZD5438, a dual candidate therapeutic for cisplatin-induced kidney injury and hearing loss. June 3rd and 4th, 2021, Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA., 2021
  • Lutze RD, Ingersoll MA, Kresock DF, Malloy EA, Caster LE, Holland EM, Teitz T. ERK1/2 inhibitor AZD-0364 Protects from Noise-Induced Hearing Loss. June 3rd and 4th, 2021, Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA., 2021
  • Malloy EA*, Ingersoll MA, Caster LE, Holland EM, Xu Z, Zallocchi M, Currier D, Liu H, He D.Z.Z., Min J, Chen T, Zuo J, Teitz T. Dabrafenib prevents cisplatin-induced hearing loss in mice. Medical Students Poster Session, 2021, Creighton University, Omaha, NE, USA. (*First Place Poster)., 2021
  • Caster LE, Ingersoll MA, Holland EM, Malloy EA, Currier D, Min J, Chen T, Zuo J, Teitz T. Investigation of small-molecule B-RAF inhibitors for protection of cochlear hair cells from cisplatin toxicity. College of Arts & Science Deans Summer Research Fellowship, Center for Undergraduate Research and Scholarship (CURAS), 2019, Creighton University, Omaha, NE, USA., Assoc. Res. Otolaryngol, 2020
  • Caster LE, Ingersoll MA, Holland EM, Malloy EA, Currier D, Min J, Chen T, Zuo J, Teitz T. Investigation of small-molecule B-RAF inhibitors for protection of cochlear hair cells from cisplatin toxicity. Association for Research in Otolaryngology (ARO) 43rd Annual Midwinter Meeting 2020, San Jose, CA., USA., Assoc. Res. Otolaryngol, 2020
  • Ingersoll MA, Caster LE, Holland EM, Malloy EA, Xu Z, Feng H, Currier D, Min J, Chen T, Zuo J, Teitz T. Repurposing an FDA approved Drug Dabrafenib for Protection from Noise- and Cisplatin-Induced Hearing Loss. Association for Research in Otolaryngology (ARO) 43rd Annual Midwinter Meeting 2020, Podium # 146, San Jose, CA., USA., ARO annual Meeting, 2020
  • Gene expression and pathway analysis of cisplatin-treated cochlear cells. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Poster # 199, Baltimore, MD., USA., Assoc. Res. Otolaryngol, 2019
  • Abstract for Meeting: Development of Small Molecule Protein Kinase Inhibitors for Hearing Protection (last author), ARO annual Meeting, 42nd ARO Annual Meeting, 44, 2019
  • Molecular simulations of CDK2 inhibitors that prevent ototoxicity effect of cisplatin. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Poster # 466, Baltimore, MD., USA., Assoc. Res. Otolaryngol, 2019
  • Ingersoll MA, DiGuiseppi J, Caster LE, Xu Z, Currier D, Zallochi ML, Min J, Chen T, Zuo J, Teitz T. Development of Small-Molecule Protein Kinase Inhibitors for Hearing Protection. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Podium # 26, Baltimore, MD., USA., ARO annual Meeting, 2019

Presentations

  • Gave a presentation in the 5th Chinese Hearing Research Conference on our research studies , Beijing, China 2019, titled "Drug Development for Cisplatin- and Noise- induced Hearing Loss.", 2019
  • Research Rounds and Seminars at Department of Pharmacology and Neuroscience, 2019

Research and Scholarship

Research and Scholarship Interests

  • - Therapeutic intervention for chemotherapy-induced, noise-induced and age-related hearing
       loss.
    - Function and protection of sensory cells in the mouse cochlea.
    - Repurposing FDA-approved drugs for hearing loss and acute kidney injury caused by 
      cisplatin chemotherapy.

Current Research Projects

  • Citations to date- 2,074. h-index -19.

Grant Funding Received

  • Title: Repurposing an FDA Approved Drug, B-RAF Kinase Inhibitor Dabrafenib for Protection from Cisplatin- And Noise- Induced Hearing Loss.
  • Title: Tamiflu as a Therapeutic Candidate for Noise-Induced Hearing Loss.
  • Title: Drug Development to Treat Hearing Disorders.
  • Cyclin-dependent Kinase-2 Inhibitor AZD5438 as a Candidate Therapeutic for Age-related Hearing Loss.
  • Title: Tamiflu as a Therapeutic Candidate for Cisplatin-Induced Hearing Loss.
  • Title: Repurposing an FDA Approved Drug, B-Raf kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise-induced Hearing Loss. Research Project leader
  • Darby Keirns (Creighton Medical student), Mentor: Dr. Tal Teitz Title: Investigating Pyrvinium Pamoate as a Therapeutic Candidate for Cisplatin-Induced Hearing Loss
  • Emma A. Malloy (Creighton Medical Student), Mentor: Dr. Tal Teitz Title: Testing ERK inhibitor Against Cisplatin-Induced Hearing Loss in Mice.
  • Lauryn E. Caster (Creighton Undergraduate Student), Mentor: Dr. Tal Teitz. Title: Investigation of PDGFR as a Potential Drug Inhibitor Target to Successfully Protect Cochlear Hair Cells from Cisplatin Ototoxicity.
  • Ingersoll (PI), Mentor: Dr. Tal Teitz Title: Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss.
  • Ingersoll (PI), Mentor: Dr. Tal Teitz Title: Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing Loss.
  • Lutze (PI), Mentor: Dr. Tal Teitz Title: ERK Inhibitor as a Potential Therapeutic Candidate for Noise-Induced Hearing Loss.